Second autologous bone marrow transplantation in Hodgkin's disease.
We report a case of sustained disease-free survival following second autologous marrow transplantation (BMT) in a patient with Hodgkin's lymphoma which had recurred following several conventional chemotherapy regimens as well as a prior autologous transplant. The initial autologous BMT was performed in fourth complete remission and followed high-dose cyclophosphamide, etoposide and thiotepa. The disease recurred 8 months later and the patient underwent a second ABMT following conditioning with busulfan and cyclophosphamide 1 year after his first transplant. Aside from slow engraftment, his course was uncomplicated. This patient remains in complete remission more than 4 years and 6 months following the second transplantation. This case demonstrates that second autologous transplantation can result in sustained disease-free survival in individuals with Hodgkin's disease with recurrence following initial transplantation.
Avalos
B R
BR
Department of Internal Medicine, Ohio State University, Columbus 43210.
Copelan
E A
EA
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D006085:Graft Survival; D006689:Hodgkin Disease / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D008297:Male; D012086:Reoperation; D013997:Time Factors; D014182:Transplantation, Autologous